43 results on '"Celestino, Joseph"'
Search Results
2. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer
- Author
-
Young Han, Chae, Bedia, Jacob S., Yang, Wei-Lei, Hawley, Sarah J., Bergan, Lindsay, Hopper, Marika, Celestino, Joseph, Guo, Jing, Gornet, Terrie G., Soosaipillai, Antoninus, Yang, Hailing, Doskocil, Samantha D., Lokshin, Anna E., Handy, Beverly C., Diamandis, Eleftherios P., Moore, Richard G., Lu, Karen H., Lu, Zhen, Anderson, Karen S., Drescher, Charles W., Skates, Steven J., and Bast, Jr, Robert C.
- Published
- 2024
- Full Text
- View/download PDF
3. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
- Author
-
Wong, Kwong-Kwok, Bateman, Nicholas W., Ng, Chun Wai, Tsang, Yvonne T. M., Sun, Charlotte S., Celestino, Joseph, Nguyen, Tri V., Malpica, Anais, Hillman, R. Tyler, Zhang, Jianhua, Futreal, P. Andrew, Rojas, Christine, Conrads, Kelly A., Hood, Brian L., Dalgard, Clifton L., Wilkerson, Matthew D., Phippen, Neil T., Conrads, Thomas P., Maxwell, George L., Sood, Anil K., and Gershenson, David M.
- Published
- 2022
- Full Text
- View/download PDF
4. Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications
- Author
-
Melendez, Brenda, Shah, Sarita, Jiang, Yunyun, Dottino, Joseph, Watson, Emma, Pearce, Hannah, Borthwick, Mikayla, Schmandt, Rosemarie E., Zhang, Qian, Cumpian, Kayleah, Celestino, Joseph, Fellman, Bryan, Yuan, Ying, Lu, Karen H., Mikos, Antonios G., and Yates, Melinda S.
- Published
- 2021
- Full Text
- View/download PDF
5. Normal Risk Ovarian Screening Study: 21-Year Update.
- Author
-
Han, Chae Young, Lu, Karen H., Corrigan, Gwen, Perez, Alexandra, Kohring, Sharlene D., Celestino, Joseph, Bedi, Deepak, Bedia, Enrique, Bevers, Therese, Boruta, David, Carlson, Matthew, Holman, Laura, Leeds, Leroy, Mathews, Cara, McCann, Georgia, Moore, Richard G., Schlumbrecht, Matthew, Slomovitz, Brian, Tobias, Dan, and Williams-Brown, Yvette
- Published
- 2024
- Full Text
- View/download PDF
6. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
- Author
-
Lee, Sanghoon, Zhao, Li, Rojas, Christine, Bateman, Nicholas W., Yao, Hui, Lara, Olivia D., Celestino, Joseph, Morgan, Margaret B., Nguyen, Tri V., Conrads, Kelly A., Rangel, Kelly M., Dood, Robert L., Hajek, Richard A., Fawcett, Gloria L., Chu, Randy A., Wilson, Katlin, Loffredo, Jeremy L., Viollet, Coralie, Jazaeri, Amir A., Dalgard, Clifton L., Mao, Xizeng, Song, Xingzhi, Zhou, Ming, Hood, Brian L., Banskota, Nirad, Wilkerson, Matthew D., Te, Jerez, Soltis, Anthony R., Roman, Kristin, Dunn, Andrew, Cordover, David, Eterovic, Agda Karina, Liu, Jinsong, Burks, Jared K., Baggerly, Keith A., Fleming, Nicole D., Lu, Karen H., Westin, Shannon N., Coleman, Robert L., Mills, Gordon B., Casablanca, Yovanni, Zhang, Jianhua, Conrads, Thomas P., Maxwell, George L., Futreal, P. Andrew, and Sood, Anil K.
- Published
- 2020
- Full Text
- View/download PDF
7. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy
- Author
-
Sakellariou-Thompson, Donastas, Forget, Marie-Andrée, Hinchcliff, Emily, Celestino, Joseph, Hwu, Patrick, Jazaeri, Amir A., Haymaker, Cara, and Bernatchez, Chantale
- Published
- 2019
- Full Text
- View/download PDF
8. Learnings, Issues, and Challenges Encountered by Students and Faculty Members in the Implementation of Small Private Online Courses (SPOCs).
- Author
-
Geronimo, Cecilia A., Adriano, Raquel C., and Celestino, Joseph Roy F.
- Subjects
LEARNING ,ONLINE education ,QUESTIONNAIRES ,LOGISTIC regression analysis ,BANDWIDTH allocation - Abstract
Consistent with the Plan-Do-Check-Act (PDCA) design of ISO 9001:2015, performance evaluation of policies pertaining to the University's main functions, i.e., instruction, research, and extension, should be pursued, especially for a newly implemented policy. Small Private Online Courses (SPOCs) at Bulacan State University were crafted, developed, and enhanced not only in compliance with the demands of continuing education but also to suit the standard of learning that is equal to classroom instruction catered physically. Whether these courses became effective and efficient within the duration of implementation remains to be determined. In the hope of having a fair and honest assessment that will lead towards relevant refinement of offering SPOCs, this mixed method of research undertaking aims to re-examine its efficiency and effectiveness, specifically, the learnings, issues and challenges encountered by the faculty members and students when using SPOC as modality. The survey questionnaire and interview questions were developed and validated and the interview among faculty members were face to face while the survey questionnaire for the SPOC students was through Google form for answering online, and the respondents were five thousand and eight students and twenty-five faculty members were interviewed. The findings indicate the factors that may impede the success of the implementation of SPOCs, aside from personal logistic challenges, the lack of discipline to manage time and sustain the interest in a given lesson are problems that require attention and further innovation. While connectivity can be identified as a personal logistic challenge, it can also be a challenge on the part of the University. The problem of connectivity may be seen as an opportunity for the University to create its own Learning Management System that can be customized to suit fit according to bandwidth, accessible and affordable to students. It can be concluded that SPOC is a promising learning platform in a world where hybrid interactions are highly relevant and can help save a lot of time and resources which brings in the recommendation to revisit, redesign, and recalibrate it for the ever-changing landscape of education. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity
- Author
-
Zhang, Qian, Schmandt, Rosemarie, Celestino, Joseph, McCampbell, Adrienne, Yates, Melinda S., Urbauer, Diana L., Broaddus, Russell R., Loose, David S., Shipley, Gregory L., and Lu, Karen H.
- Published
- 2014
- Full Text
- View/download PDF
10. Insulin-Like Growth Factor Binding Protein 2 Promotes Glioma Development and Progression
- Author
-
Dunlap, Sarah M., Celestino, Joseph, Wang, Hua, Jiang, Rongcai, Holland, Eric C., Fuller, Gregory N., and Zhang, Wei
- Published
- 2007
- Full Text
- View/download PDF
11. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer.
- Author
-
Zhao, Li, Corvigno, Sara, Ma, Shaolin, Celestino, Joseph, Fleming, Nicole D., Hajek, Richard A., Lankenau Ahumada, Adrian, Jennings, Nicholas B., Thompson, Erika J., Tang, Hongli, Westin, Shannon N., Jazaeri, Amir A., Zhang, Jianhua, Futreal, P. Andrew, Sood, Anil K., and Lee, Sanghoon
- Subjects
ADJUVANT chemotherapy ,OVARIAN tumors ,SEQUENCE analysis ,ONCOGENES ,RNA ,MOLECULAR biology ,TREATMENT effectiveness ,GENE expression profiling ,DESCRIPTIVE statistics ,TUMOR markers ,EXTRACELLULAR vesicles ,LONGITUDINAL method - Abstract
Simple Summary: Ovarian cancer is the deadliest gynecological malignancy worldwide, and the biggest issue faced by patients is disease relapse after primary treatment. Understanding up front how patients will respond to therapy is an important and compelling challenge. On these premises, our goal was to understand if a simple blood sample can give us this information, before the patients start chemotherapy. We determined that circulating extracellular vesicles isolated at diagnosis can distinguish between patients who will respond differently to the treatment. These results, if corroborated, will pave the way for a novel, much needed predictive marker of response. Patients with high-grade serous ovarian cancer (HGSC) who have no visible residual disease (R0) after primary surgery have the best clinical outcomes, followed by patients who undergo neoadjuvant chemotherapy (NACT) and have a response enabling interval cytoreductive surgery. Clinically useful biomarkers for predicting these outcomes are still lacking. Extracellular vesicles (EVs) have been recognized as liquid biopsy-based biomarkers for early cancer detection and disease surveillance in other disease settings. In this study, we performed extensive molecular characterization of serum-derived EVs and correlated the findings with therapeutic outcomes in patients with HGSC. Using EV-DNA whole-genome sequencing and EV-RNA sequencing, we identified distinct somatic EV-DNA alterations in cancer-hallmark genes and in ovarian cancer genes, as well as significantly altered oncogenic pathways between the R0 group and NACT groups. We also found significantly altered EV-RNA transcriptomic variations and enriched pathways between the groups. Taken together, our data suggest that the molecular characteristics of EVs could enable prediction of patients with HGSC who could undergo R0 surgery or respond to chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53
- Author
-
Co, Ngai Na, Iglesias, David, Celestino, Joseph, Kwan, Suet Y., Mok, Samuel C., Schmandt, Rosemarie, and Lu, Karen H.
- Published
- 2014
- Full Text
- View/download PDF
13. Chemopreventive effects of metformin on obesity-associated endometrial proliferation
- Author
-
Zhang, Qian, Celestino, Joseph, Schmandt, Rosemarie, McCampbell, Adrienne S., Urbauer, Diana L., Meyer, Larissa A., Burzawa, Jennifer K., Huang, Marilyn, Yates, Melinda S., Iglesias, David, Broaddus, Russell R., and Lu, Karen H.
- Published
- 2013
- Full Text
- View/download PDF
14. Enhanced estrogen-induced proliferation in obese rat endometrium
- Author
-
Zhang, Qian, Shen, Qi, Celestino, Joseph, Milam, Michael R., Westin, Shannon N., Lacour, Robin A., Meyer, Larissa A., Shipley, Gregory L., Davies, Peter J.A., Deng, Lei, McCampbell, Adrienne S., Broaddus, Russell R., and Lu, Karen H.
- Published
- 2009
15. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
- Author
-
Milam, Michael R., Celestino, Joseph, Wu, Weiguo, Broaddus, Russell R., Schmeler, Kathleen M., Slomovitz, Brian M., Soliman, Pamela T., Gershenson, David M., Wang, Hong, Ellenson, Lora H., and Lu, Karen H.
- Published
- 2007
16. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo
- Author
-
Dai, Chengkai, Celestino, Joseph C., Okada, Yoshifumi, Louis, David N., Fuller, Greory N., and Holland, Eric C.
- Subjects
Cytochemistry -- Research ,Astrocytes -- Research ,Cell differentiation -- Research ,Neuroglia -- Physiological aspects ,Carcinogenesis -- Research ,Cell proliferation -- Genetic aspects ,Autocrine mechanisms -- Research ,Oligodendroglia -- Research ,Biological sciences - Abstract
Some low-grade oligodendrogliomas may be made up of proliferating glial progenitor cells blocked in ability to differentiate based on new research. Malignant gliomas have acquired other mutations as well. Chronic autocrine PDGF signaling can promote a proliferating population of glial precursors potentially adequate to bring on gliomagenesis.
- Published
- 2001
17. Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor–Negative Mammary Tumors
- Author
-
Lu, Chunhua, Speers, Corey, Zhang, Yun, Xu, Xiaochun, Hill, Jamal, Steinbis, Emily, Celestino, Joseph, Shen, Qiang, Kim, Heetae, Hilsenbeck, Susan, Mohsin, Syed K., Wakeling, Alan, Osborne, C. Kent, and Brown, Powel H.
- Published
- 2003
18. If looks could kill: morphologic subtypes of high-grade serous ovarian cancer
- Author
-
Handley, Katelyn, Sims, Travis, Glassman, Deanna, Fleming, Nicole, Lee, Sanghoon, Fellman, Bryan, Yao, Hui, Yao, Jun, Liu, Jinsong, Bast, Robert, Lu, Zhen, Westin, Shannon, Rangel, Kelly, Celestino, Joseph, Bateman, Nicholas, Conrads, Thomas, Maxwell, George, Ram, Prahlad, and Sood, Anil
- Published
- 2021
- Full Text
- View/download PDF
19. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
- Author
-
Yang, Wei‐Lei, Lu, Zhen, Guo, Jing, Fellman, Bryan M., Ning, Jing, Lu, Karen H., Menon, Usha, Kobayashi, Makoto, Hanash, Samir M., Celestino, Joseph, Skates, Steven J., Bast, Robert C., Yang, Wei-Lei, and Bast, Robert C Jr
- Subjects
OVARIAN cancer ,EARLY detection of cancer ,RECEIVER operating characteristic curves ,ANTIGENS ,CANCER ,OVARIAN epithelial cancer - Abstract
Background: Early detection of ovarian cancer could significantly improve patient outcomes. Cancer antigen 125 (CA 125) is elevated in sera from approximately 60% of patients with early-stage (I/II) disease. Sensitivity might be improved through the combination of CA 125 with other biomarkers. Among potential biomarkers, antigen-autoantibody (Ag-AAb) complexes have received relatively little attention.Methods: Luminex-based immunoassays were used to measure human epididymis protein 4 (HE4), anti-HE4 autoantibody, and HE4 Ag-AAb complexes in sera from patients with early- (n = 73) and late-stage ovarian cancers (n = 49) at the time of diagnosis and from asymptomatic women with (n = 15) or without ovarian cancer (n = 212) enrolled in the Normal Risk Ovarian Cancer Screening Study.Results: At 98% specificity for healthy, asymptomatic women, 7% of patients with early-stage (I/II) ovarian cancer and 4% of patients with late-stage (III/IV) disease had elevated levels of HE4 autoantibody, whereas elevated levels of HE4 Ag-AAb complexes were detected in sera from 38% of early-stage cases and 31% of late-stage cases. Complementarity was observed in receiver operating characteristic (ROC) curves between HE4 Ag-AAb complexes and CA 125 levels in early-stage ovarian cancer (P < .001). CA 125 detected 63% of cases, and a combination of CA 125 and HE4 Ag-AAb complexes detected 81%. Complementarity was also observed in ROC curves for an independent validation set with 69 early-stage patients (P = .039). HE4 Ag-AAb complexes were detected in serial preclinical serum samples from women destined to develop ovarian cancer: they correlated with CA 125 but did not provide a lead time.Conclusions: HE4 Ag-AAb complexes could complement CA 125 in detecting a higher fraction of early-stage ovarian cancers. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
20. KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary.
- Author
-
Hillman, R. Tyler, Celestino, Joseph, Terranova, Christopher, Beird, Hannah C., Gumbs, Curtis, Little, Latasha, Nguyen, Tri, Thornton, Rebecca, Tippen, Samantha, Jianhua Zhang, Lu, Karen H., Gershenson, David M., Rai, Kunal, Broaddus, Russell R., and Futreal, P. Andrew
- Subjects
GRANULOSA cell tumors ,OVARIAN tumors ,CANCER genes ,FISHER exact test ,DISEASE relapse ,OVARIAN follicle - Abstract
Adult-type granulosa cell tumors of the ovary (aGCTs) are rare gynecologic malignancies that exhibit a high frequency of somatic FOXL2 c.C402G (p.Cys134Trp) mutation. Treatment of relapsed aGCT remains a significant clinical challenge. Here we show, using whole-exome and cancer gene panel sequencing of 79 aGCTs from two independent cohorts, that truncating mutation of the histone lysine methyltransferase gene KMT2D (also known as MLL2) is a recurrent somatic event in aGCT. Mono-allelic KMT2D-truncating mutations are more frequent in recurrent (10/44, 23%) compared with primary (1/35, 3%) aGCTs (p = 0.02, two-sided Fisher’s exact test). IHC detects additional non-KMT2D-mutated aGCTs with loss of nuclear KMT2D expression, suggesting that non-genetic KMT2D inactivation may occur in this tumor type. These findings identify KMT2D inactivation as a novel driver event in aGCTs and suggest that mutation of this gene may increase the risk of disease recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.
- Author
-
How, Jeffrey, Westin, Shannon Neville, Sims, Travis T., Lito, Kathryn, Celestino, Joseph, Rangel, Kelly M., Peng, Weiyi, Wang, Linghua, and Jazaeri, Amir A.
- Published
- 2023
- Full Text
- View/download PDF
22. Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.
- Author
-
Ring, Kari L., Yates, Melinda S., Schmandt, Rosemarie, Onstad, Michaela, Qian Zhang, Celestino, Joseph, Suet-Ying Kwan, and Lu, Karen H.
- Abstract
Objectives: The aims of this study were to determine if activating KRas mutation alters estrogen signaling in endometrial cancer (EC) and to explore the potential therapeutic impact of these alterations. Methods: The Cancer Genome Atlas was queried for changes in estrogen-regulated genes in EC based on KRas mutation status. In vitro studies were conducted to evaluate estrogen receptor α (ERα) phosphorylation changes and related kinase changes in KRas mutant EC cells. The resulting effect on response to MEK inhibition, using trametinib, was evaluated. Immunohistochemistry was performed on KRas mutant and wild-type EC tumors to test estrogen signaling differences. Results: KRas mutant tumors in The Cancer Genome Atlas showed decreased progesterone receptor expression (P = 0.047). Protein analysis in KRas mutant EC cells also showed decreased expression of ERα (P G 0.001) and progesterone receptor (P = 0.001). Although total ERα is decreased in KRas mutant cells, phospho-ERα S118 was increased compared with wild type. Treatment with trametinib in KRas mutant cells increased phospho-ERα S167 and increased expression of estrogen-regulated genes. While MEK inhibition blocked estradiol-stimulated phosphorylation of ERK1/2 and p90RSK in wildtype cells, phospho-ERK1/2 and phospho-p90RSK were substantially increased in KRas mutants. KRas mutant EC tumor specimens showed similar changes, with increased phospho-ERα S118 and phospho-ERα S167 compared with wild-type EC tumors. Conclusions: MEK inhibition in KRas mutant cells results in activation of ER signaling and prevents the abrogation of signaling through ERK1/2 and p90RSK that is achieved in KRas wild-type EC cells. Combination therapy with MEK inhibition plus antiestrogen therapy may be necessary to improve response rates in patients with KRas mutant EC. Key Words: Endometrial cancer, Estrogen signaling, KRas, MEK inhibitor [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.
- Author
-
Iglesias, David A., Qian Zhang, Celestino, Joseph, Sun, Charlotte C., Yates, Melinda S., Schmandt, Rosemarie E., and Lu, Karen H.
- Abstract
Objectives: Obesity is a major risk factor for endometrial cancer. We evaluated whether obesity exacerbates progression of endometrial hyperplasia (EH) using the PR
Cre/+ PTENflox/+ mouse model and examined if the type 2 diabetes drug, metformin, could prevent EH. Methods: Twenty obese (PRCre/+ PTENflox/+ ) mice were maintained on a high-fat diet, while 20 lean mice ate a matching low-fat diet. Ten mice from each group received metformin (1,000 mg/day) in drinking water. Mice were euthanized at 26 weeks. Uterine tissue was scored for degree of EH. Immunohistochemical staining for Ki67 was used to evaluate cellular proliferation. Markers of PI3K/AKT/mTOR activity were evaluated by immunohistochemistry using activation-specific antibodies. Serum adiponectin was quantified by ELISA. Results: Obesity had no effect on the extent of EH in (PRCre/+ PTENflox/+ ) mice. While metformin significantly altered circulating adiponectin levels in obese and lean animals, it had no effect on EH. There were no differences in endometrial proliferation as measured by Ki67 staining. Neither obesity nor metformin altered PI3K/AKT/mTOR activity in these animals. Conclusions: Weight and metformin did not affect the severity of EH resulting from PTEN inactivation. Alternative mouse models of early endometrial cancer are required for preclinical cancer prevention studies. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
24. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.
- Author
-
Handley, Katelyn F., Sims, Travis T., Bateman, Nicholas W., Glassman, Deanna, Foster, Katherine I., Lee, Sanghoon, Yao, Jun, Yao, Hui, Fellman, Bryan M., Liu, Jinsong, Lu, Zhen, Conrads, Kelly A., Hood, Brian L., Barakat, Waleed, Zhao, Li, Zhang, Jianhua, Westin, Shannon N., Celestino, Joseph, Rangel, Kelly M., and Badal, Sunil
- Published
- 2022
- Full Text
- View/download PDF
25. A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer.
- Author
-
Fahrmann, Johannes F., Irajizad, Ehsan, Kobayashi, Makoto, Vykoukal, Jody, Dennison, Jennifer B., Murage, Eunice, Wu, Ranran, Long, James P., Do, Kim-Anh, Celestino, Joseph, Lu, Karen H., Lu, Zhen, Bast Jr., Robert C., Hanash, Samir, and Dinulescu, Daniela M.
- Subjects
OVARIAN tumors ,BLOOD plasma ,ONCOGENES ,EARLY detection of cancer ,AMINES ,MASS spectrometry ,TUMOR markers ,RECEIVER operating characteristic curves ,TUMOR antigens ,DATA analysis - Abstract
Simple Summary: There is a need for additional marker(s) to detect early-stage ovarian cancer that would augment the performance of CA125. Herein, we report a polyamine signature that is detected in the blood and that has value for detecting ovarian cancers at an early stage. The polyamine signature was able to complement CA125 in identifying more ovarian cancer cases that would have been missed by CA125 alone. Our validation of a polyamine signature provides compelling evidence for the value of blood polyamine metabolites as markers for ovarian cancer detection. MYC is an oncogenic driver in the pathogenesis of ovarian cancer. We previously demonstrated that MYC regulates polyamine metabolism in triple-negative breast cancer (TNBC) and that a plasma polyamine signature is associated with TNBC development and progression. We hypothesized that a similar plasma polyamine signature may associate with ovarian cancer (OvCa) development. Using mass spectrometry, four polyamines were quantified in plasma from 116 OvCa cases and 143 controls (71 healthy controls + 72 subjects with benign pelvic masses) (Test Set). Findings were validated in an independent plasma set from 61 early-stage OvCa cases and 71 healthy controls (Validation Set). Complementarity of polyamines with CA125 was also evaluated. Receiver operating characteristic area under the curve (AUC) of individual polyamines for distinguishing cases from healthy controls ranged from 0.74–0.88. A polyamine signature consisting of diacetylspermine + N-(3-acetamidopropyl)pyrrolidin-2-one in combination with CA125 developed in the Test Set yielded improvement in sensitivity at >99% specificity relative to CA125 alone (73.7% vs 62.2%; McNemar exact test 2-sided P: 0.019) in the validation set and captured 30.4% of cases that were missed with CA125 alone. Our findings reveal a MYC-driven plasma polyamine signature associated with OvCa that complemented CA125 in detecting early-stage ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Chemopreventive effects of metformin on obesity-associated endometrial proliferation.
- Author
-
Qian Zhang, Celestino, Joseph, Schmandt, Rosemarie, McCampbell, Adrienne S., Urbauer, Diana L., Meyer, Larissa A., Burzawa, Jennifer K., Huang, Marilyn, Yates, Melinda S., Iglesias, David, Broaddus, Russell R., and Lu, Karen H.
- Subjects
METFORMIN ,OBESITY ,ENDOMETRIAL cancer risk factors ,CANCER chemoprevention ,CANCER cell proliferation ,INSULIN resistance ,HYPERINSULINISM ,LABORATORY rats - Abstract
OBJECTIVE: Obesity is a significant contributing factor to endometrial cancer risk. We previously demonstrated that estrogen-induced endometrial proliferation is enhanced in the context of hyper-insulinemia and insulin resistance. In this study, we investigate whether pharmacologic agents that modulate insulin sensitivity or normalize insulin levels will diminish the proliferative response to estrogen. STUDY DESIGN: Zucker fa/fa obese rats and lean controls were used as models of hyperinsulinemia and insulin resistance. Insulin levels were depleted in ovariectomized rats following treatment with streptozotocin, or modulated by metformin treatment. The number of BrdU-incorporated cells, estrogen-dependent proliferative and antiproliferative gene expression, and activation of mTOR and ERK1/2 MAPK signaling were studied. A rat normal endometrial cell line RENE1 was used to evaluate the direct effects of metformin on endometrial cell proliferation and gene expression in vitro. RESULTS: Streptozotocin lowered circulating insulin levels in obese rats and decreased the number of BrdU-labeled endometrial cells even in the presence of exogenous estrogen. Treatment with the insulin-sensitizing drug metformin attenuated estrogen-dependent proliferative expression of c-myc and c-fos in the obese rat endometrium compared to untreated controls and was accompanied by inhibition of phosphorylation of the insulin and IGF1 receptors (IRβ/IGF1R) and ERK1/2. In vitro studies indicated metformin inhibited RENE1 proliferation in a dose-dependent manner. CONCLUSION: These findings suggest that drugs that modulate insulin sensitivity, such as metformin, hinder estrogen-mediated endometrial proliferation. Therefore, these drugs may be clinically useful for the prevention of endometrial cancer in obese women. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
27. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis.
- Author
-
Kobayashi, Makoto, Katayama, Hiroyuki, Irajizad, Ehsan, Vykoukal, Jody V., Fahrmann, Johannes F., Kundnani, Deepali L., Yu, Chuan-Yih, Cai, Yining, Hsiao, Fu Chung, Yang, Wei-Lei, Lu, Zhen, Celestino, Joseph, Long, James P., Do, Kim-Ann, Lu, Karen H., Ladd, Jon J., Urban, Nicole, Bast Jr., Robert C., and Hanash, Samir M.
- Subjects
ANTIGEN-antibody reactions ,AUTOANTIBODIES ,IMMUNOGLOBULINS ,MASS spectrometry ,OVARIAN tumors ,RECOMBINANT proteins ,PROTEOMICS ,PROTEIN microarrays - Abstract
Harnessing the immune response to tumor antigens in the form of autoantibodies, which occurs early during tumor development, has relevance to the detection of cancer at early stages. We conducted an initial screen of antigens associated with an autoantibody response in serous ovarian cancer using recombinant protein arrays. The top 25 recombinants that exhibited increased reactivity with cases compared to controls revealed TP53 and MYC, which are ovarian cancer driver genes, as major network nodes. A mass spectrometry based independent analysis of circulating immunoglobulin (Ig)-bound proteins in ovarian cancer and of ovarian cancer cell surface MHC-II bound peptides also revealed a TP53–MYC related network of antigens. Our findings support the occurrence of a humoral immune response to antigens linked to ovarian cancer driver genes that may have utility for early detection applications. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.
- Author
-
Holland, Eric C., Celestino, Joseph, Dai, Chengkai, Schaefer, Laura, Sawaya, Raymond E., and Fuller, Gregory N.
- Subjects
- *
GLIOBLASTOMA multiforme , *MICE physiology , *PROTEINS - Abstract
Gliomas are the most common primary malignant brain tumours and are classified into four clinical grades, with the most aggressive tumours being grade 4 astrocytomas (also known as glioblastoma multiforme; GBM). Frequent genetic alterations in GBMs (refs 2-5) result in stimulation of common signal transduction pathways involving Ras, Akt and other proteins. It is not known which of these pathways, if any, are sufficient to induce GBM formation. Here we transfer, in a tissue-specific manner, genes encoding activated forms of Ras and Akt to astrocytes and neural progenitors in mice. We found that although neither activated Ras nor Akt alone is sufficient to induce GBM formation, the combination of activated Ras and Akt induces highgrade gliomas with the histological features of human GBMs. These tumours appear to arise after gene transfer to neural progenitors, but not after transfer to differentiated astrocytes. Increased activity of RAS is found in many human GBMs (ref. 11), and we show here that Akt activity is increased in most of these tumours, implying that combined activation of these two pathways accurately models the biology of this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
29. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.
- Author
-
Guo, Jing, Yang, Wei-Lei, Pak, Daewoo, Celestino, Joseph, Lu, Karen H., Ning, Jing, Lokshin, Anna E., Cheng, Zhongping, Lu, Zhen, and Bast, Robert C.
- Subjects
AUTOANTIBODY analysis ,OVARIAN tumors ,BIOMARKERS ,CYTOKINES ,INTERLEUKINS ,LYMPHOKINES ,TUMOR classification ,RECEIVER operating characteristic curves ,EARLY detection of cancer ,DIAGNOSIS ,TUMOR risk factors - Abstract
Early detection of ovarian cancer promises to reduce mortality. While serum CA125 can detect more than 60% of patients with early stage (I–II) disease, greater sensitivity might be observed with a panel of biomarkers. Ten protein antigens and 12 autoantibody biomarkers were measured in sera from 76 patients with early stage (I–II), 44 patients with late stage (III–IV) ovarian cancer and 200 healthy participants in the normal risk ovarian cancer screening study. A four-biomarker panel (CA125, osteopontin (OPN), macrophage inhibitory factor (MIF), and anti-IL-8 autoantibodies) detected 82% of early stage cancers compared to 65% with CA125 alone. In early stage subjects the area under the receiver operating characteristic curve (AUC) for the panel (0.985) was significantly greater (p < 0.001) than the AUC for CA125 alone (0.885). Assaying an independent validation set of sera from 71 early stage ovarian cancer patients, 45 late stage patients and 131 healthy women, AUC in early stage disease was improved from 0.947 with CA125 alone to 0.974 with the four-biomarker panel (p = 0.015). Consequently, OPN, MIF and IL-8 autoantibodies can be used in combination with CA125 to distinguish ovarian cancer patients from healthy controls with high sensitivity. Osteopontin appears to be a robust biomarker that deserves further evaluation in combination with CA125. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. STK15 F31I polymorphism is associated with increased uterine cancer risk: A pilot study
- Author
-
Milam, Michael R., Gu, Jian, Yang, Hushan, Celestino, Joseph, Wu, Weiguo, Horwitz, Irwin B., Lacour, Robin A., Westin, Shannon N., Gershenson, David M., Wu, Xifeng, and Lu, Karen H.
- Subjects
- *
CANCER patients , *CANCER risk factors , *CANCER in women , *SMOKING - Abstract
Abstract: Objective. : STK15 is a serine threonine kinase which assists chromosomal separation and mitotic spindle stability through interaction with the centrosome during mitosis. We hypothesized that STK15 polymorphisms might modulate the risk of uterine cancer. Methods. : We used a hospital-based case–control study to assess the association between STK15 polymorphisms and risk of uterine cancer. Cases and controls were matched on age, race, and smoking status. Two common STK15 single nucleotide polymorphisms (SNPs), F31I (T/A), and V57I (G/A), were genotyped. Odds ratios (OR) and 95% confidence intervals (CI) were obtained using unconditional logistic regression analysis. Results. : A total of 193 women with uterine cancer and 218 controls were genotyped for both SNPs. After adjustment for age, race, and smoking status for the F31I SNP, the homozygous variant genotype (AA) was associated with a significantly increased uterine cancer risk (OR 10.2; 95% CI 2.23–46.5). Individuals with the heterozygous genotype (TA) and a history of tobacco use also exhibited an increased risk for uterine cancer (OR 2.63; 95% CI 1.20–5.76). For the V57I SNP, neither the homozygous (AA) nor the heterozygous (GA) variant genotypes were associated with significantly altered risk for uterine cancer (OR 0.76; 95% CI 0.18–3.25 and OR 0.88; 95% CI 0.52–1.49). Conclusion. : Our study demonstrates that STK15 F31I SNP is associated with an increased risk for uterine cancer. Confirmation of this pilot study is needed in a larger case–control population to evaluate this genetic variant with other known risk factors for uterine cancer. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
31. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial.
- Author
-
How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, and Jazaeri AA
- Abstract
Background: The efficacy and feasibility of pembrolizumab combined with chemotherapy in frontline management of advanced high-grade epithelial ovarian cancer (EOC) is unknown. Additionally, modification of the tumor microenvironment following neoadjuvant therapy is not well understood., Methods: In this single-arm phase 2 trial (this study was registered at ClinicalTrials.gov: NCT02520154), eligible patients received up to 4 cycles of neoadjuvant chemotherapy followed by interval cytoreduction, 3 cycles of adjuvant intravenous carboplatin/weekly paclitaxel/pembrolizumab, and finally maintenance pembrolizumab until progression or toxicity (maximum 20 cycles). The primary endpoint was progression-free survival (PFS). Secondary endpoints included feasibility, toxicity, and overall survival (OS). PD-L1 staining, multiplex immunofluorescence staining, RNA sequencing, reverse-phase protein array analyses were performed on pre- and post-chemotherapy samples., Findings: Thirty-one eligible patients were enrolled. Median PFS and OS was 14.88 (95% CI 12.39-23.00) and 57.43 months (95% CI 30.88-not reached), respectively. Among those with PD-L1 combined positive score (CPS) ≥10, the median PFS and OS were not reached compared to those with CPS <10 (10.50 and 30.90 months, respectively). Feasibility was met, with all patients completing their planned adjuvant cycles. Treatment discontinuation due to immune-related toxicity occurred in 6 patients (20%). Chemotherapy resulted in an infiltration of anti-tumor immune cells in the tumor microenvironment. Samples of patients with the best PFS demonstrated increased expression of NF-κB, TGF-β, and β-catenin signaling., Conclusions: Pembrolizumab with chemotherapy was feasible and resulted in PFS within the historical range for this EOC population. Patients with CPS ≥10 may benefit more from this regimen, and future studies should investigate this potential biomarker., Funding: This investigator-initiated trial was funded by Merck., Competing Interests: Declaration of interests S.N.W. reports grants from NIH, GOG Foundation, Cotinga Pharmaceuticals, Bayer, and ArQule during the conduct of the study. She also reports grants and personal fees from AstraZeneca, Clovis Oncology, GlaxoSmithKline/Tesaro, Roche/Genentech, and Novartis. She reports personal fees from Merck, Pfizer, Eisai, CIrculogene, Zentalis, and Agenus outside the submitted work. N.D.F. reports personal fees from Tesaro, Pfizer, Bristol Myers Squibb, and GlaxoSmithKline outside the submitted work. A.K.S. discloses the following competing interests: consulting (Merck, GSK, ImmunoGen, Iylon, Kiyatec, Astra Zeneca, Onxeo) and shareholder (BioPath). R.C. reports the following competing interests: consulting (Clovis Oncology, Genentech/Roche, AstraZeneca/MedImmune, Genmab, OncoMed, Immunogen, AbbVie, Agenus, Novocure, Merck, OncXerna Therapeutics, Alkermes, Gradalis, GlaxoSmithKline, Alkermes, Eisai, GOG Foundation, Karyopharm Therapeutics), employment (Vanium Group, US Oncology Network), leadership (Onsexo), stock and other ownership interests (McKesson/US Oncology Network), and research funding (AstraZeneca/MedImmune, Clovis Oncology, Merck, Roche/Genentech, Immunogen, Mirati Therapeutics, Amgen, Pfizer, Lilly, Regeneron, Alkermes, Karyopharm Therapeutics). A.A.J. reports personal fees from Gerson Lehrman Group, Guidepoint, Iovance advisory board, NuProbe, Simcere, PACT Pharma, Genentech-Roche, Eisai, Agenus, and Macrogenics. He also reports grants from AstraZeneca, Bristol Myers Squibb, Iovance, Aravive, Pfizer, Immatics US, Eli Lilly, and Merck, and stock/stock options from AvengeBio outside the submitted work., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Long-term follow-up of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer reveals relapse characterized by immune exhaustion.
- Author
-
Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, and Yates MS
- Abstract
Background: Nonsurgical treatment options are increasingly needed for endometrial atypical hyperplasia (AH) and endometrioid endometrial cancer (EEC). Despite promising initial response rates, prospective long-term data and determinants for relapse are limited., Methods: Follow-up data from patients in our prospective phase II trial of LIUD for AH/G1EEC were collected from medical records. Spatial transcriptomics (Nanostring GeoMX digital spatial profiling) with in silico cell type deconvolution and pathway analyses were employed on longitudinal biopsy samples from five patients across pre-treatment, on-treatment, and relapse., Results: Of 43 participants exhibiting initial response to LIUD, 41 had follow-up data. Sixteen (39%) experienced relapse. Clinical factors associated with shorter response duration included younger age, initial diagnosis of G1EEC, lack of response at six months, premenopausal status, and Hispanic ethnicity (p<0.05), but only six-month response status remained a significant predictor in a multivariate model (p=0.023). LIUD increased abundance of NK cells (DMCP-counter score=46.13, FDR=0.004) and cytotoxic lymphocytes (DMCP-counter score=277.67, FDR=0.004), as well as lymphocyte cytotoxicity markers PRF1 (log2FC=1.62, FDR=0.025) and GZMA (log2FC=2.47, FDR=0.008). NK cells were reduced at relapse (DMCP-counter score=-55.96, FDR=0.02). Immune-related pathways (IFNα-response and TGFβ-signaling) were enriched at relapse (FDR<0.05). IDO1 expression, reflecting immune exhaustion, was upregulated at relapse (FDR<0.05)., Conclusions: Upfront resistance and relapse after initial response to LIUD for AH/G1EEC impacts nearly half of patients, remaining a major hurdle for non-surgical treatment of AH/G1EEC. Molecular studies evaluating longitudinal biopsies from a small cohort implicate immune mechanisms at relapse, including reversal of progestin-related immunomodulation and increased immune exhaustion.
- Published
- 2024
- Full Text
- View/download PDF
33. Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer.
- Author
-
Bowen MB, Melendez B, Zhang Q, Moreno D, Peralta L, Chan WK, Jeter C, Tan L, Zal MA, Lorenzi PL, Dunner K, Yang RK, Broaddus RR, Celestino J, Gokul N, Whitley E, Schmandt R, Lu K, Kim HE, and Yates MS
- Abstract
Lynch syndrome (LS) is defined by inherited mutations in DNA mismatch repair genes, including MSH2, and carries 60% lifetime risk of developing endometrial cancer (EC). Beyond hypermutability, specific mechanisms for LS-associated endometrial carcinogenesis are not well understood. Here, we assessed the effects of MSH2 loss on EC pathogenesis using a novel mouse model (PR-Cre Msh2
flox/flox , abbreviated Msh2KO), primary cell lines established from this model, human tissues, and human EC cell lines with isogenic MSH2 knockdown. Beginning at eight months of age, 30% of Msh2KO mice exhibited endometrial atypical hyperplasia (AH), a precancerous lesion. At 12 to 16 months of age, 47% of Msh2KO mice exhibited either AH or ECs with histologic features similar to human LS-related ECs. Transcriptomic profiling of EC from Msh2KO mice revealed a transcriptomic signature for mitochondrial dysfunction. Studies in vitro and in vivo revealed mitochondrial dysfunction based upon two mechanisms: marked mitochondrial content reduction, along with pronounced disruptions to the integrity of retained mitochondria. Human LS-related ECs also exhibited mitochondrial content reduction compared with non-LS-related ECs. Functional studies revealed metabolic reprogramming of MSH2-deficient EC cells in vitro , including reduced oxidative phosphorylation and increased susceptibility to glycolysis suppression. We are the first to identify mitochondrial dysfunction and metabolic disruption as a consequence of MSH2 deficiency-related EC. Mitochondrial and metabolic aberrations should be evaluated as novel biomarkers for endometrial carcinogenesis or risk stratification and could serve as targets for cancer interception in women with LS., Significance: This is the first study to report mitochondrial dysfunction contributing to MSH2-deficient endometrial cancer development, identifying a noncanonical pathway for MSH2 deficient carcinogenesis, which also imparts vulnerability to metabolic targeting.- Published
- 2024
- Full Text
- View/download PDF
34. Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors.
- Author
-
Khlebus E, Vuttaradhi VK, Welte T, Khurana N, Celestino J, Beird HC, Gumbs C, Little L, Legarreta AF, Fellman BM, Nguyen T, Lawson B, Ferri-Borgogno S, Mok SC, Broaddus RR, Gershenson DM, Futreal PA, and Hillman RT
- Subjects
- Adult, Female, Humans, Tumor Microenvironment genetics, Neoplasm Recurrence, Local genetics, Hormones, Granulosa Cell Tumor genetics, Granulosa Cell Tumor pathology
- Abstract
Adult-type granulosa cell tumors (aGCT) are rare ovarian sex cord tumors with few effective treatments for recurrent disease. The objective of this study was to characterize the tumor microenvironment (TME) of primary and recurrent aGCTs and to identify correlates of disease recurrence. Total RNA sequencing (RNA-seq) was performed on 24 pathologically confirmed, cryopreserved aGCT samples, including 8 primary and 16 recurrent tumors. After read alignment and quality-control filtering, DESeq2 was used to identify differentially expressed genes (DEG) between primary and recurrent tumors. Functional enrichment pathway analysis and gene set enrichment analysis was performed using "clusterProfiler" and "GSVA" R packages. TME composition was investigated through the analysis and integration of multiple published RNA-seq deconvolution algorithms. TME analysis results were externally validated using data from independent previously published RNA-seq datasets. A total of 31 DEGs were identified between primary and recurrent aGCTs. These included genes with known function in hormone signaling such as LHCGR and INSL3 (more abundant in primary tumors) and CYP19A1 (more abundant in recurrent tumors). Gene set enrichment analysis revealed that primarily immune-related and hormone-regulated gene sets expression was increased in recurrent tumors. Integrative TME analysis demonstrated statistically significant depletion of cancer-associated fibroblasts in recurrent tumors. This finding was confirmed in multiple independent datasets., Implications: Recurrent aGCTs exhibit alterations in hormone pathway gene expression as well as decreased infiltration of cancer-associated fibroblasts, suggesting dual roles for hormonal signaling and TME remodeling underpinning disease relapse., (©2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
35. A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses.
- Author
-
Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, Dennison JB, Vykoukal J, Long JP, Do KA, Drescher C, Lu K, Lu Z, Bast RC, Hanash S, and Fahrmann JF
- Subjects
- Female, Humans, CA-125 Antigen, WAP Four-Disulfide Core Domain Protein 2, Proteins metabolism, Carcinoma, Ovarian Epithelial, Biomarkers, Tumor, Algorithms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms pathology
- Abstract
Purpose: To assess the contributions of circulating metabolites for improving upon the performance of the risk of ovarian malignancy algorithm (ROMA) for risk prediction of ovarian cancer among women with ovarian cysts., Experimental Design: Metabolomic profiling was performed on an initial set of sera from 101 serous and nonserous ovarian cancer cases and 134 individuals with benign pelvic masses (BPM). Using a deep learning model, a panel consisting of seven cancer-related metabolites [diacetylspermine, diacetylspermidine, N-(3-acetamidopropyl)pyrrolidin-2-one, N-acetylneuraminate, N-acetyl-mannosamine, N-acetyl-lactosamine, and hydroxyisobutyric acid] was developed for distinguishing early-stage ovarian cancer from BPM. The performance of the metabolite panel was evaluated in an independent set of sera from 118 ovarian cancer cases and 56 subjects with BPM. The contributions of the panel for improving upon the performance of ROMA were further assessed., Results: A 7-marker metabolite panel (7MetP) developed in the training set yielded an AUC of 0.86 [95% confidence interval (CI): 0.76-0.95] for early-stage ovarian cancer in the independent test set. The 7MetP+ROMA model had an AUC of 0.93 (95% CI: 0.84-0.98) for early-stage ovarian cancer in the test set, which was improved compared with ROMA alone [0.91 (95% CI: 0.84-0.98); likelihood ratio test P: 0.03]. In the entire specimen set, the combined 7MetP+ROMA model yielded a higher positive predictive value (0.68 vs. 0.52; one-sided P < 0.001) with improved specificity (0.89 vs. 0.78; one-sided P < 0.001) for early-stage ovarian cancer compared with ROMA alone., Conclusions: A blood-based metabolite panel was developed that demonstrates independent predictive ability and complements ROMA for distinguishing early-stage ovarian cancer from benign disease to better inform clinical decision making., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
36. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection.
- Author
-
Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC Jr, Lu KH, and Koopmeiners JS
- Subjects
- Blood Proteins analysis, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Ovarian Neoplasms pathology, Protein Array Analysis, ROC Curve, Biomarkers, Tumor analysis, Blood Proteins metabolism, Cystadenocarcinoma, Serous blood, Cystadenocarcinoma, Serous pathology, Ovarian Neoplasms blood, Ovarian Neoplasms classification
- Abstract
The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over CA125 alone. In this study, we used Proseek Multiplex Oncology II plates to simultaneously measure the expression of 92 cancer-related proteins in serum using proximity extension assays. This technology combines the sensitivity of the PCR with the specificity of antibody-based detection methods, allowing multiplex biomarker detection and high-throughput quantification. We analyzed 1 μL of sera from each of 61 women with ovarian cancer and compared the values obtained with those from 88 age-matched healthy women. Principle component analysis and unsupervised hierarchical clustering separated the ovarian cancer patients from the healthy, with minimal misclassification. Data from the Proseek plates for CA125 levels exhibited a strong correlation with clinical values for CA125. We identified 52 proteins that differed significantly ( P < 0.006) between ovarian cancer and healthy samples, several of which are novel serum biomarkers for ovarian cancer. In total, 40 proteins had an estimated area under the ROC curve of 0.70 or greater, suggesting their potential to serve as biomarkers for ovarian cancer. CA125 alone achieved a sensitivity of 93.4% at a specificity of 98%. By adding the Oncology II values for five proteins to CA125 in a multiprotein classifier, we increased the assay sensitivity to 98.4% at a specificity of 98%, thereby improving the sensitivity and specificity of CA125 alone., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
37. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
- Author
-
Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, Broaddus R, Hancock JF, Schmandt R, and Lu KH
- Subjects
- Animals, Antineoplastic Agents pharmacology, Apoptosis drug effects, Apoptosis genetics, Cell Line, Tumor, Cell Proliferation drug effects, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Female, Gene Silencing, Humans, Mice, Mutation, PTEN Phosphohydrolase genetics, PTEN Phosphohydrolase metabolism, Protein Kinase C metabolism, Protein Transport, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins p21(ras), Signal Transduction drug effects, Tumor Burden drug effects, Tumor Burden genetics, Xenograft Model Antitumor Assays, ras Proteins genetics, Endometrial Neoplasms metabolism, Metformin pharmacology, Proto-Oncogene Proteins metabolism, ras Proteins metabolism
- Abstract
Metformin is an oral biguanide commonly used for the treatment of type II diabetes and has recently been demonstrated to possess antiproliferative properties that can be exploited for the prevention and treatment of a variety of cancers. The mechanisms underlying this effect have not been fully elucidated. Using both in vitro and in vivo models, we examined the effects of metformin on endometrial tumors with defined aberrations in the PI3K/PTEN/mTOR and MAPK signaling pathways to understand metformin mechanism of action and identify clinically useful predictors of response to this agent. In vitro assays of proliferation, cytotoxicity, and apoptosis were used to quantify the effects of metformin on endometrial cancer cell lines with mutations in the PI3K/PTEN/mTOR and MAPK signaling pathways. The in vivo effects of oral metformin on tumor progression were further examined using xenograft mouse models of endometrial cancer. K-Ras localization was analyzed by confocal microscopy using GFP-labeled oncogenic K-Ras and by immunoblot following subcellular fractionation. Metformin inhibited cell proliferation, induced apoptosis, and decreased tumor growth in preclinical endometrial cancer models, with the greatest response observed in cells harboring activating mutations in K-Ras. Furthermore, metformin displaces constitutively active K-Ras from the cell membrane, causing uncoupling of the MAPK signaling pathway. These studies provide a rationale for clinical trials using metformin in combination with PI3K-targeted agents for tumors harboring activating K-Ras mutations, and reveal a novel mechanism of action for metformin., (©2013 AACR.)
- Published
- 2013
- Full Text
- View/download PDF
38. A novel platform for detection of CK+ and CK- CTCs.
- Author
-
Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, and Sood AK
- Subjects
- Biomarkers, Tumor blood, Breast Neoplasms blood, Breast Neoplasms genetics, Colorectal Neoplasms blood, Colorectal Neoplasms genetics, Epithelial-Mesenchymal Transition genetics, Female, Humans, Keratins analysis, Keratins genetics, Neoplasm Metastasis, Neoplastic Cells, Circulating pathology, Ovarian Neoplasms blood, Ovarian Neoplasms genetics, Breast Neoplasms pathology, Colorectal Neoplasms pathology, Keratins blood, Neoplastic Cells, Circulating chemistry, Ovarian Neoplasms pathology
- Abstract
Unlabelled: Metastasis is a complex, multistep process that begins with the epithelial-mesenchymal transition (EMT). Circulating tumor cells (CTC) are believed to have undergone EMT and thus lack or express low levels of epithelial markers commonly used for enrichment and/or detection of such cells. However, most current CTC detection methods target only EpCAM and/or cytokeratin (CK) to enrich epithelial CTCs, resulting in failure to recognize other, perhaps more important, CTC phenotypes that lack expression of these markers. Here, we describe a population of complex aneuploid CTCs that do not express CK or CD45 antigen in patients with breast, ovarian, or colorectal cancer. These cells were not observed in healthy subjects. We show that the primary epithelial tumors were characterized by similar complex aneuploidy, indicating conversion to an EMT phenotype in the captured cells. Collectively, our study provides a new method for highly efficient capture of previously unrecognized populations of CTCs., Significance: Current assays for CTC capture likely miss populations of cells that have undergone EMT. Capture and study of CTCs that have undergone EMT would allow a better understanding of the mechanisms driving metastasis.
- Published
- 2011
- Full Text
- View/download PDF
39. Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites.
- Author
-
Ishiyama S, Matsueda S, Jones LA, Efferson C, Celestino J, Schmandt R, Ioannides CG, Tsuda N, and Chang DZ
- Subjects
- Amino Acid Sequence, Ascites immunology, Cell Line, Tumor, Dimerization, Female, HLA-A2 Antigen immunology, Humans, Immunoglobulin G immunology, Membrane Proteins chemistry, Molecular Sequence Data, Nerve Tissue Proteins chemistry, Peptides chemistry, Proteasome Endopeptidase Complex chemistry, Protein Conformation, Receptor, Notch1 chemistry, CD8-Positive T-Lymphocytes immunology, Membrane Proteins immunology, Nerve Tissue Proteins immunology, Ovarian Neoplasms immunology, Peptides immunology, Peptides isolation & purification, Receptor, Notch1 immunology
- Abstract
Notch is a plasma membrane receptor involved in the control of cell fate specification and in the maintenance of the balance between proliferation and differentiation in many cell lineages. Disruption of Notch has been implicated in a variety of hematological and solid cancers. Numb is also expressed in many adult mammalian cells. Adult cells divide symmetrically, and Numb is symmetrically partitioned at mitosis. The Numb-mediated regulation of Notch is believed to play a causative role in naturally occurring breast cancers. Reduction of Numb levels in breast tumors is regulated by proteasomal degradation. We reasoned that if the disregulated negative control of Notch by Numb protein is the consequence of Numb proteasomal degradation, then degradation of Numb can generate peptides which are transported, presented by MHC-I molecules. Surprisingly we found few candidate naturally processed peptides from Notch1, Notch2, and Numb1. CD8+ T cells expressing TCRs which specifically recognized peptides Notch1 (2112-2120) and Numb1 (87-95) were presented in the ascites of ovarian cancer patients. Many of these cells were differentiated and expressed high levels of Perforin. The natural immunogenicity of Notch1 and particularly of Numb1 suggests a mechanism of immunosurveillance which is overcome during tumor progression. Immunotherapy with tumor antigens from Notch and Numb should be important for treatment of cancer patients.
- Published
- 2007
40. EphA2 expression is associated with aggressive features in ovarian carcinoma.
- Author
-
Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, and Sood AK
- Subjects
- Adult, Aged, Aged, 80 and over, Blotting, Western, Cell Line, Tumor, Female, Humans, Immunohistochemistry, Immunoprecipitation, Middle Aged, Multivariate Analysis, Neoplasm Invasiveness, Proportional Hazards Models, Time Factors, Ovarian Neoplasms metabolism, Receptor, EphA2 biosynthesis
- Abstract
Purpose: EphA2 (epithelial cell kinase) is a transmembrane receptor tyrosine kinase that has been implicated in oncogenesis. There are no published data regarding the role of EphA2 in ovarian carcinoma, which is the focus of the present study., Experimental Design: Nontransformed (HIO-180) and ovarian cancer (EG, 222, SKOV3, and A2780-PAR) cell lines were evaluated for EphA2 by Western blot analysis. Five benign ovarian masses, 10 ovarian tumors of low malignant potential, and 79 invasive ovarian carcinomas were also evaluated for EphA2 expression by immunohistochemistry. All samples were scored in a blinded fashion. Univariate and multivariate analyses were used to determine significant associations between EphA2 expression and clinicopathological variables., Results: By Western blot analysis, EG, 222, and SKOV3 cell lines overexpressed EphA2, whereas A2780-PAR and HIO-180 had low to absent EphA2 expression. All of the benign tumors had low or absent EphA2 expression. Among the invasive ovarian carcinomas examined (mean age of patients was 59.2 years), 60 (75.9%) tumors overexpressed EphA2 and the other 19 tumors had negative or minimal EphA2 expression. There was no association of EphA2 overexpression with ascites, likelihood of nodal positivity, pathological subtype, and optimum surgical cytoreduction (residual tumor <1 cm). However, EphA2 overexpression was significantly associated with higher tumor grade (P = 0.02) and advanced stage of disease (P = 0.001). The median survival for patients with tumor EphA2 overexpression was significantly shorter (median, 3.1 years; P = 0.004); the median survival for patients with low or absent EphA2 tumor expression was at least 12 years and has not yet been reached. In multivariate analysis using the Cox proportional hazards model, only volume of residual disease (P < 0.04) and EphA2 overexpression (P < 0.01) were significant and independent predictors of survival., Conclusions: EphA2 overexpression is predictive of aggressive ovarian cancer behavior and may be an important therapeutic target.
- Published
- 2004
- Full Text
- View/download PDF
41. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
- Author
-
Wu W, Slomovitz BM, Celestino J, Chung L, Thornton A, and Lu KH
- Subjects
- Adenocarcinoma, Clear Cell metabolism, Adenocarcinoma, Clear Cell pathology, Carcinoma, Papillary metabolism, Carcinoma, Papillary pathology, Cystadenocarcinoma, Papillary metabolism, Cystadenocarcinoma, Papillary pathology, Cystadenocarcinoma, Serous metabolism, Cystadenocarcinoma, Serous pathology, Estrogen Receptor alpha, Female, Humans, Immunohistochemistry, Middle Aged, Neoplasm Proteins biosynthesis, Phosphorylation, Receptors, Estrogen metabolism, Receptors, Progesterone biosynthesis, Uterine Neoplasms metabolism, Uterine Neoplasms pathology, Carcinoma, Endometrioid metabolism, Carcinoma, Endometrioid pathology, Cell Cycle Proteins biosynthesis, Endometrial Neoplasms metabolism, Endometrial Neoplasms pathology, Receptors, Estrogen biosynthesis, cdc25 Phosphatases biosynthesis
- Abstract
Overexpression of cdc25B, an important cell cycle regulator, has been shown to result in mammary gland hyperplasia in transgenic mice and to increase steroid hormone responsiveness as a direct coactivator of the estrogen receptor (ER). We investigated the potential role of cdc25B in the pathogenesis of endometrial carcinomas in conjunction with ER-alpha. We examined the expression of cdc25B and phosphorylated ER-alpha in 4 archived human specimens of normal endometrium; 7 endometrial hyperplasia with or without atypia; 32 endometrioid endometrial carcinoma (EEC), including 20 low-grade (grade 1) and 12 high-grade (grade 2 or 3) tumors; and 18 endometrial cancers with aggressive histological subtypes (uterine papillary serous carcinoma and clear cell carcinoma, UPSC/CCC) by immunohistochemistry with monoclonal antibodies. Expression of cdc25B and phosphorylated ER-alpha was increased in endometrial hyperplasia and atypical hyperplasia compared with normal secretory endometrium. Ninety percent (18 of 20) of the low-grade EEC expressed cdc25B at a high level, whereas only 42% (5 of 12) of the high-grade EEC did so (chi(2) = 8.7; P < 0.01). Sixty-five percent (13 of 20) of the low-grade EEC expressed phosphorylated ER-alpha at high levels, but only 17% (2 of 12) of high-grade EEC did so (chi(2) = 7.0; P < 0.01). Coordinate high-level expression of phosphorylated ER-alpha and cdc25B occurred in 65% (13 of 20) of low-grade EEC but in only 17% (2 of 12) of the high-grade EEC (chi(2) = 7.0; P < 0.01). In the UPSC/CCC tumors, only 22% (4 of 18) of the tumors expressed phosphorylated ER-alpha at high-levels. However, 83% (15 of 18) of these carcinomas showed high expression of cdc25B (chi(2) = 13.5; P < 0.01). The majority of the UPSC/CCC (15 of 18) did not show coordinate high expression of phosphorylated ER-alpha and cdc25B. Our findings show that in endometrial hyperplasia and low-grade EEC, coordinate increase in cdc25B and phosphorylated ER-alpha occurs. However, in UPSC/CCC, cdc25B is highly expressed without coordinate increase in phosphorylated ER-alpha. Cdc25B may play important roles in the development and progression of EEC and UPSC/CCC by different mechanisms.
- Published
- 2003
42. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
- Author
-
Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, and Brown PH
- Subjects
- Animals, Bexarotene, Cell Division drug effects, Female, Gene Expression drug effects, Genes, erbB-2, Mammary Glands, Animal cytology, Mammary Glands, Animal drug effects, Mammary Neoplasms, Experimental genetics, Mammary Neoplasms, Experimental metabolism, Mammary Neoplasms, Experimental pathology, Mammary Tumor Virus, Mouse, Mice, Mice, Transgenic, Receptors, Estrogen physiology, Retinoid X Receptors, Transgenes drug effects, Transgenes genetics, Anticarcinogenic Agents pharmacology, Mammary Neoplasms, Experimental prevention & control, Receptors, Retinoic Acid metabolism, Tetrahydronaphthalenes pharmacology, Transcription Factors metabolism
- Abstract
Despite the effectiveness of the selective estrogen receptor (ER) modulators in preventing ER-positive breast cancer, chemopreventive agents still need to be developed for the prevention of ER-negative breast cancers. The naturally occurring retinoids are promising agents for the prevention of human cancers but are too toxic for long-term chronic use. We previously demonstrated that the chemopreventive effects of the retinoids could be separated from the toxicity by using an RXR-selective retinoid, LGD1069. The studies described here demonstrate that LGD1069 effectively suppresses ER-negative tumor development in mouse mammary tumor virus-erbB2 transgenic mice with minimal toxicity. These studies suggest that receptor-selective retinoids are promising agents for the prevention of breast cancer and that they may be particularly useful in preventing ER-negative breast cancer.
- Published
- 2002
43. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
- Author
-
Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, and Holland EC
- Subjects
- Animals, Astrocytes enzymology, Astrocytes pathology, Astrocytes physiology, Brain Neoplasms enzymology, Brain Neoplasms pathology, Enzyme Activation, Gene Deletion, Gene Expression Regulation, Genes, ras genetics, Glioblastoma enzymology, Glioblastoma pathology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Neurons enzymology, Neurons pathology, Neurons physiology, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-akt, Signal Transduction genetics, Stem Cells enzymology, Stem Cells pathology, Stem Cells physiology, Transfection, Brain Neoplasms genetics, Cell Transformation, Neoplastic genetics, Cyclin-Dependent Kinase Inhibitor p16 genetics, Glioblastoma genetics, Protein Serine-Threonine Kinases, Proto-Oncogene Proteins metabolism, Tumor Suppressor Protein p14ARF genetics, ras Proteins physiology
- Abstract
Deletion of the INK4a-ARF locus is found in the majority of human malignant gliomas. However, the role of INK4a-ARF loss in gliomagenesis is unclear. Animal modeling has shown that mice with targeted deletions in the Ink4a-Arf gene do not develop spontaneous gliomas. We have previously reported that combined KRas and Akt signaling could induce glioblastoma (GBM) formation from neural progenitor cells but had no effect in differentiated astrocytes. In this investigation, we have studied the effects of Ink4a-Arf loss on the formation of GBM induced by KRas and Akt gene transfer into neural progenitor cells and astrocytes. We show here that Ink4a-Arf deficiency allows for GBM formation from astrocytes and that it enhances tumor incidence in neural progenitor cells. Furthermore, KRas alone can cooperate with deletion of the Ink4a-Arf locus in tumor formation from both neural progenitor cells and astrocytes. The resulting tumors were nestin positive and resembled a spectrum of glioma morphologies ranging in astrocytic character depending on cell-of-origin and presence of activated Akt. Our data strongly supports the view that one role of loss of Ink4a-Arf in gliomagenesis could be to sensitize astrocytes to transformation through dedifferentiation in response to the appropriate oncogenic stimuli.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.